肠内营养支持辅助治疗非酒精性脂肪肝患者的疗效分析  

Clinical Analysis of Enteral Nutrition Support in Adjuvant Therapy of Patients with Non-alcoholic Fatty Liver Disease

作　　者：杨妙浪 

机构地区：[1]广州医科大学附属第二医院,广东广州510280

出　　处：《中国医学创新》2016年第11期65-68,共4页Medical Innovation of China

摘　　要：目的：观察肠内营养支持辅助治疗非酒精性脂肪肝（NAFLD）患者的疗效及对血清超氧物歧化酶（SOD）和白细胞介素-17（IL-17）水平的影响。方法：选取2012年6月-2014年7月本院收治的NAFLD患者82例作为研究对象,按照随机数字表法分为治疗组和对照组,每组41例。对照组给予口服还原型谷胱甘肽片（4片/次,3次/d）和口服多烯磷脂酰胆碱胶囊（3次/d,1粒/次）治疗;治疗组在对照组基础上加用肠内营养支持治疗,注入瑞代肠内营养液,常规为20~30 kcal/（kg·d）。比较两组治疗12周后总胆固醇（TC）、甘油三酯（TG）和低密度脂蛋白胆固醇（LDL-C）水平、两组临床疗效及两组血清超氧物歧化酶（SOD）和白细胞介素-17（IL-17）水平。结果：治疗后,治疗组TC、LDL-C和TG水平均明显低于对照组,比较差异圴有统计学意义（P〈0.05）;治疗组总有效率为95.12%,明显高于对照组的75.61%,比较差异有统计学意义（P〈0.05）;治疗后,治疗组血清SOD水平明显高于对照组,IL-17水平明显低于对照组,比较差异均有统计学意义（P〈0.05）。结论：肠内营养支持辅助治疗NAFLD可明显改善患者血脂水平,提高临床疗效,上调血清SOD和抑制IL-17水平可能为其作用机制之一。Objective：To observe the clinical efficacy of enteral nutrition support in adjuvant therapy of patients with non-alcoholic fatty liver disease（NAFLD） and its influences on serum levels of superoxide dismutase（SOD） and interleukin-17（IL-17）.Method：A total of 82 cases of NAFLD in our hospital from June 2012 to July 2014 were selected as the research objects,they were randomly divided into the control group and the treatment group,each group had 41 cases.The control group was given oral administration of Reduced Glutathione Tablets（4 pieces/time,3 times/d） and Polyene Phosphatidylcholine Capsules（1 pieces/time,3 times/d）,the treatment group based on the control group use of enteral nutrition support treatment,injection of enteral nutrition liquid,conventional 20~30 kcal/（kg·d）.After 12 weeks of treatment,the total cholesterol（TC）,triglyceride（TG）,low density lipoprotein cholesterol（LDL-C） levels,the clinical curative rate,serum superoxide dismutase（SOD） and white blood cell-17（IL-17） levels in two groups were compared.Result：After treatment,the treatment group TC,LDL-C and TG levels were significantly lower than the control group,the differences were statistically significant（P〈0.05）.The total effective rate of the treatment group was 95.12%,significantly higher than that of the control group 75.61%,the difference was statistically significant（P〈0.05）.After treatment,the level of serum SOD in the treatment group was significantly higher than that in the control group,IL-17 levels was significantly lower than the control group,the differences were statistically significant（P〈0.05）.Conclusion：Enteral nutrition support in adjuvant therapy of patients with NAFLD can effectively improve blood fat levels and clinical treatment effect,and up regulation of serum SOD and inhibiting IL-17 level may be one of the mechanisms of its action.

关 键 词：肠内营养 非酒精性脂肪肝 超氧物歧化酶 白细胞介素-17 

分 类 号：R575.5[医药卫生—消化系统]